Document Detail

Update on nephrolithiasis management.
MedLine Citation:
PMID:  17912227     Owner:  NLM     Status:  MEDLINE    
Urolithiasis affects 10%-15% of the population in their lifetime. After spontaneous passage or surgical treatment, a subset of these patients will have recurrent calculi. These recurrent stone events are significantly morbid and can potentially lead to serious chronic renal disease, thus prevention is a very important treatment goal. Fortunately, a reversible metabolic abnormality can be identified in over 90% of recurrent stone formers. Thus, a detailed metabolic evaluation using 24 hour urine collections and serum tests is indicated in patients at high risk for stone recurrence. Once the patient's underlying urinary physicochemical and physiologic derangements are defined, targeted medical therapy can be initiated in order to prevent growth of pre-existing stones and recurrent stone formation. In this paper, we provide a review of the currently available selective and nonselective pharmacologic treatments for urolithiasis. Furthermore, we discuss a number of investigational agents for kidney stone prevention. Although many of these agents are effective, there remain numerous clinical scenarios where currently available therapies are inadequate.
L O Long; S Park
Related Documents :
7960537 - Development of metaphylaxis in calcium urolithiasis: a restriction of conventional drug...
11805407 - Minimally invasive pcnl in patients with renal pelvic and calyceal stones.
15924257 - Removal of ureteral stones with extracorporeal shock wave lithotripsy and ureteroscopic...
2672837 - Cholecystectomy: the gold standard.
25340017 - Primary angioplasty for symptomatic atherosclerotic middle cerebral artery stenosis.
22407057 - Three-hour interval drain clamping reduces postoperative bleeding in total knee arthrop...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Minerva urologica e nefrologica = The Italian journal of urology and nephrology     Volume:  59     ISSN:  0393-2249     ISO Abbreviation:  Minerva Urol Nefrol     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-10-03     Completed Date:  2008-04-04     Revised Date:  2008-06-23    
Medline Journal Info:
Nlm Unique ID:  8503649     Medline TA:  Minerva Urol Nefrol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  317-25     Citation Subset:  IM    
Department of Urology, University of Washington Medical Center, Seattle, WA 98195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Nephrolithiasis / classification,  diagnosis*,  physiopathology,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dyslipidaemia in chronic kidney disease.
Next Document:  Acute renal failure: outcomes and risk of chronic kidney disease.